Recro Pharma, Inc. (REPH) is a publicly traded company in the Unknown sector. Across all available filings, 30 corporate insiders have executed 359 transactions totaling $42.0M, demonstrating a bearish sentiment with -$10.9M in net insider flow. The most recent transaction on Mar 15, 2022 involved a purchase of 512 shares valued at $1.0K.
No significant insider buying has been recorded for REPH in the recent period.
No significant insider selling has been recorded for REPH in the recent period.
Based on recent SEC filings, insider sentiment for REPH is bearish with an Insider Alignment Score of 37/100 and a net flow of -$10.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Recro Pharma, Inc. (REPH) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 30 insiders are actively trading REPH stock, having executed 359 transactions in the past 90 days. The most active insider is Capital, Llc Broadfin (Executive), who has made 21 transactions totaling $12.7M.
Get notified when executives and directors at REPH file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 15, 2022 | David Enloe J. Jr | Executive | Purchase | 512 | $1.96 | $1.0K | |
| Feb 15, 2022 | David Enloe J. Jr | Executive | Purchase | 571 | $1.77 | $1.0K | |
| Feb 3, 2022 | David Lake Ryan | Executive | Payment | 1,021 | $1.54 | $1.6K | |
| Jan 31, 2022 | David Lake Ryan | Executive | Payment | 1,419 | $1.54 | $2.2K | |
| Jan 20, 2022 | David Enloe J. Jr | Executive | Award | 66,007 | $N/A | $0 | |
| Jan 20, 2022 | David Enloe J. Jr | Executive | Award | 303,030 | $N/A | $0 | |
| Jan 20, 2022 | David Lake Ryan | Executive | Award | 169,697 | $N/A | $0 | |
| Jan 20, 2022 | David Lake Ryan | Executive | Award | 39,604 | $N/A | $0 | |
| Jan 18, 2022 | David Lake Ryan | Executive | Payment | 1,094 | $1.65 | $1.8K | |
| Jan 18, 2022 | David Enloe J. Jr | Executive | Purchase | 602 | $1.68 | $1.0K | |
| Jan 3, 2022 | David Lake Ryan | Executive | Payment | 979 | $1.74 | $1.7K | |
| Dec 31, 2021 | David Lake Ryan | Executive | Payment | 28,730 | $1.71 | $49.1K | |
| Dec 21, 2021 | Company, Inc. Awm Investment | Executive | Sale | 99,398 | $1.55 | $154.1K | |
| Dec 16, 2021 | Company, Inc. Awm Investment | Executive | Sale | 50,000 | $1.61 | $80.5K | |
| Dec 15, 2021 | Company, Inc. Awm Investment | Executive | Sale | 20,000 | $1.63 | $32.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 167 | $26.5M | 60.8% |
Purchase(P) | 27 | $15.5M | 35.7% |
Payment(F) | 49 | $1.0M | 2.3% |
Exercise(M) | 39 | $521.2K | 1.2% |
Award(A) | 65 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Conversion(C) | 10 | $0 | 0.0% |
Insider selling pressure at Recro Pharma, Inc. has increased, with 30 insiders executing 359 transactions across all time. Total sales of $26.5M significantly outpace purchases of $15.5M, resulting in a net outflow of $10.9M. This selling activity appears largely discretionary, which may warrant closer attention from investors.